MedTrace Logo

Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine

NCT01289938 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2016-05-13

No results posted yet for this study

Summary

Pharmacokinetic of Metoclopramide (MCP) in correlation to polymorphisms of CYP2D6 and Dopamine-D2-Receptor. Pharmacokinetic of Diphenhydramine (DPH) in correlation to polymorphisms of CYP2D6

Conditions

  • Drug Metabolism, Poor, CYP2D6-RELATED

Interventions

DRUG

Diphenhydramine

Diphenhydramine 50 mg oral once

DRUG

Metoclopramide

10 mg i.v. metoclopramide once

Sponsors & Collaborators

  • Matthias Schwab

    lead OTHER

Principal Investigators

  • Matthias Schwab, MD · UKT

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289938 on ClinicalTrials.gov